iv opioid
ApprovedSmall molecule
Biogeniv opioid is one of 52 small molecule programs targeting Multiple Sclerosis. It is currently in Approved.
2
Indications
6
Total Trials
0
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
560 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1iv opioid
BiogenApproved
Kesimpta
NovartisPreclinical
Tysabri
BiogenPreclinical
Campath
GGenzyme, a Sanofi Company
Preclinical
Zinbryta
RochePreclinical
Flomax
SanofiPreclinical
Pred Forte
NovartisPreclinical
Myfortic
NovartisPreclinical
Novantrone
PfizerPreclinical
Proair HFA
GGlaxo Dba Glaxosmithkline
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Multiple Sclerosis1 trial
Laparoscopic Cholecystectomy1 trial
1 more indication
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for iv opioid. EMBL-EBI & Wellcome Sanger Institute.
- [4]